Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy

Anti-CD20 therapies have revolutionized the treatment of B-cell malignancies. Despite these advances, relapsed and refractory disease remains a major treatment challenge. The optimization of CD20-targeted immunotherapies is considered a promising strategy to improve current therapies. However, resea...

Descripción completa

Detalles Bibliográficos
Autores principales: Dias, Joana N. R., Almeida, André, André, Ana S., Aguiar, Sandra I., Bule, Pedro, Nogueira, Sara, Oliveira, Soraia S., Carrapiço, Belmira, Gil, Solange, Tavares, Luís, Aires-da-Silva, Frederico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854400/
https://www.ncbi.nlm.nih.gov/pubmed/35177658
http://dx.doi.org/10.1038/s41598-022-06549-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854400/
https://www.ncbi.nlm.nih.gov/pubmed/35177658
http://dx.doi.org/10.1038/s41598-022-06549-1

Ejemplares similares